Advertisement

Article Types

Jump To:

Regular Article

Maximum length for a Regular Article is 4,000 words of text - counting only the Introduction, Methods, Results, and Discussion. The text abstract is limited to 250 words. Submissions are limited to a total of 7 figures, and digital images are required. We recommend a limit of 100 references. The sections of a Regular Article should be ordered as follows:

  • Abstract
  • Key Points
  • Introduction
  • Methods (must include sufficient information to allow readers to understand the article content)
  • Results
  • Discussion
  • Acknowledgements
  • Authorship Contributions
  • Disclosure of Conflicts of Interest
  • References
  • Tables
  • Figure Legends
  • Figures
  • Visual Abstract

Supplemental data may include additional information regarding methodology, supplemental figures or tables, or primary data sets; it must be submitted with the original manuscript submission so it can be peer reviewed.

Any involvement of medical writers/researchers, particularly those employed or supported by the pharmaceutical industry, in the writing of an article must be clearly defined and disclosed in the Authorship and/or the Acknowledgements section(s) as appropriate. This type of involvement must also be disclosed to the Editor-in-Chief in the Cover Letter.

Exceptional Case Report

Single-case reports or small case series of exceptional novelty are considered in Blood Advances if they offer truly important data elucidating disease biology or therapy. The description of the case must be sufficiently complete to highlight the underlying biology that is being described with additional studies. It is expected that these case reports will provide novel insights or therapeutic opportunities that will be of broad relevance and interest.  

Exceptional Case Reports should include no more than 1,200 words of text, 25 references, and 2 figures or tables. No text abstract should be included; submission of a visual abstract is optional. The sections of an Exceptional Case Report should be ordered as follows:

  • Key Points
  • Introduction
  • Case description
  • Methods
  • Results and discussion
  • Acknowledgements
  • Authorship Contributions
  • Disclosure of Conflicts of Interest
  • References
  • Tables
  • Figure Legends
  • Figures
  • Visual Abstract (optional)

Any involvement by pharmaceutical or medical device company employees or medical writers supported by a pharmaceutical or medical device company in the writing of this article must be disclosed to the Editor-in-Chief in the cover letter and must also be clearly defined and disclosed in the Authorship and/or Acknowledgements section(s) of the manuscript as appropriate. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.

Stimulus Reports

These are short-format, scientific “case reports” on findings from either the clinic or the laboratory that are novel, but not necessarily definitive, scientific observations. These articles are designed to stimulate new insight and next steps in translational or basic research. 

These articles should include no more than 1,200 words of text, 25 references, and 2 figures or tables. No text abstract should be included; submission of a visual abstract is optional. The sections of a Stimulus Report should be ordered as follows:

  • Key Points
  • Introduction
  • Methods
  • Results and discussion
  • Acknowledgements
  • Authorship Contributions
  • Disclosure of Conflicts of Interest
  • References
  • Tables
  • Figure Legends
  • Figures
  • Visual Abstract (optional)

Other article types

Review Article

Review Articles are welcomed by the Journal and are generally solicited by the Editor-in-Chief; authors wishing to submit an unsolicited Review Article are invited to contact the Editor-in-Chief prior to submission in order to screen the proposed topic for relevance and priority, given other review articles that may already be in preparation. Review Articles should focus on recent scientific or clinical advances in an area of broad interest to those in the field of hematology. Such articles must be concise and critical and should include appropriate references to the literature. All Review Articles, including those solicited by the Editors, are rigorously peer reviewed before a final publication decision is made.

Review Articles should not exceed 4,000 words in length; the abstract must not exceed 250 words; submission of a visual abstract is optional; we recommend a limit of 100 references. These articles should have no more than 3 authors. Permission to include more than 3 authors must be granted by the Editor-in-Chief. The use of tables and color figures to summarize critical points is encouraged; the Journal offers assistance with preparation or improvement of figures by professional illustrators, once the article is accepted.

Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing Reviews. The use of editing services for non-English speakers is permissible, but it must be disclosed. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.

Drug Advances

Drug Advances is a collaborative article type where two individuals each present a particular viewpoint, one basic science or preclinical and the other clinical, of a new drug or indication relevant to hematology. Each two-part article is intended to present both the basic science/development and the clinical applications of new drugs or new indications for a drug. All applications and/or indications should meet FDA approval standards.

These articles should be no more than 4,000 words total and should review important and relevant scientific works that form the basis of a particular opinion with appropriate references yet do not need to be exhaustive reviews. The articles should be integrated to provide a consistent writing style; individual perspectives and experiences are welcome. Drug Advances articles should have an abstract of no more than 250 words and up to 7 figures. Visual Abstracts are optional.

Any involvement by pharmaceutical or medical device company employees or medical writers supported by a pharmaceutical or medical device company in the writing of this article must be disclosed to the Editor-in-Chief in the cover letter and must also be clearly defined and disclosed in the Authorship and/or Acknowledgements section(s) of the manuscript as appropriate. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.

Point-Counterpoint

Point-Counterpoint is a debate based article type where two individuals or groups each present contrasting opinions on a particular topic in order to highlight an important biological, clinical or therapeutic debate. These composite articles are intended to present different opinions about an important topic with the intent of informing our readership, stimulating discussion and inviting comment.

These articles should be no more than 1,500 words each and should review important scientific works that form the basis of a particular opinion with appropriate references. Point-Counterpoint articles have no abstract. There can be up to two figures or tables. There will be an opportunity for interested readers to offer their own opinions in an open format.

Any involvement by pharmaceutical or medical device company employees or medical writers supported by a pharmaceutical or medical device company in the writing of this article must be disclosed to the Editor-in-Chief in the cover letter and must also be clearly defined and disclosed in the Authorship and/or Acknowledgements section(s) of the manuscript as appropriate. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.

Blood Advances Commentary

The journal accepts original communications that bring out a focused but novel or important message on basic or clinical topics in hematology as well as communications that relate to articles published in Blood Advances but also contain significant new primary data. All clinical submissions must have been approved by an ethics committee or institutional review board. Consideration for publication will be based on priority and interest to readership as determined by Editorial evaluation and peer review. A Response from the author of an original article may be invited by Editors.

Commentaries include no more than 1,200 words of text, 25 references, and 2 figures or tables. Commentaries have no abstract. A clear title is required. Commentaries are indexed by Medline, and appear in PubMed. Submission fees do not apply to Commentaries.

Blood Advances Talks (BATs)

Blood Advances Talks (BATs) are intended to provide educational or scholarly material in an audio format. BATs are generally solicited by the Editor-in-Chief; authors wishing to submit unsolicited BATs are invited to contact the Editor-in-Chief prior to submission in order to screen the proposed topic for relevance and priority, given other BATs that may already be in preparation.

BATs should be 10-15 minutes in length and develop a topic in depth but presented in an audio format. Submissions should include a title page containing any acknowledgments, authorship contribution statements and conflict of interest disclosure; an abstract of up to 250 words; and a script of about 1000-1500 words. The topic should be such that it can be adequately covered in a 10-15 minute long audio presentation.

Pharmaceutical or medical device company employees and medical writers supported by a pharmaceutical or medical device company are not permitted to have any role in writing BATs. The use of editing services for non-English speakers is permissible, but it must be disclosed. Please direct any questions regarding this policy to the Editor-in-Chief prior to submission.